Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).
H5463 is a Rhode Island health and human services bill focused on lowering Medicaid prescription drug costs by increasing oversight of managed care organizations (MCOs) and pharmacy benefit managers (PBMs). The bill states an intent to protect Rhode Islanders and the Medicaid program from high drug prices by requiring greater transparency, accountability, and reporting from entities that manage pharmacy benefits for Medicaid enrollees.
The bill amends the duties of the secretary of the Executive Office of Health and Human Services (EOHHS) to expand oversight of Medicaid policy, budgeting, reporting, and program coordination. It also adds specific requirements for EOHHS to monitor and regulate PBM and MCO practices, including prohibiting spread pricing, requiring pass-through pricing, limiting discriminatory treatment of independent pharmacies, and restricting utilization management practices such as prior authorization, step therapy, and non-medical drug switching when they delay or reduce medically necessary care. EOHHS would also be directed to analyze broader structural options for Medicaid pharmacy benefits, such as creating a single Medicaid PBM, carving pharmacy benefits out of managed care, adopting a uniform preferred drug list, or moving to a Connecticut-style Medicaid model.
In addition to PBM oversight, the bill reinforces EOHHS’s existing responsibilities for Medicaid coordination, data reporting, budget preparation, quality improvement, and interdepartmental management. It requires the secretary to continue producing detailed annual Medicaid expenditure and utilization reports and to use objective data in policy planning. The bill also references broader health and human services administration, including integrated eligibility systems, long-term care rebalancing, and consumer-centered service delivery.
The general sentiment reflected in the bill text is strongly supportive of tighter state control over Medicaid pharmacy spending and more direct accountability from PBMs and MCOs. Because there are no committee transcripts or recorded votes provided, there is no documented opposition or debate in the available context. The bill’s framing suggests a consumer- and cost-protection approach, with emphasis on transparency, patient outcomes, and state fiscal responsibility.
Notable points of contention likely center on the restrictions placed on PBM and MCO business practices, especially the ban on spread pricing, limits on utilization management tools, and the possibility of restructuring Medicaid pharmacy benefits. These provisions could draw concern from managed care plans, PBMs, and potentially insurers or pharmacy benefit administrators, while independent pharmacies, Medicaid advocates, and consumer groups would likely view them favorably. The bill also authorizes civil fines and enforcement actions, which may be a further point of dispute.
The bill would amend Rhode Island law governing the Executive Office of Health and Human Services by adding explicit duties related to Medicaid oversight, reporting, and policy review, and by directing EOHHS to regulate PBM and MCO conduct in the Medicaid program. It would require contractual and operational changes affecting Medicaid managed care arrangements, including pricing models, pharmacy reimbursement practices, and benefit management procedures, and would authorize enforcement through regulations, staffing, and civil penalties of up to $10,000 per violation. The bill would also influence Medicaid program administration more broadly by requiring analysis of alternative pharmacy benefit structures and continued reporting on expenditures, outcomes, and utilization.
The available materials indicate a generally favorable, reform-oriented sentiment toward the bill, with the stated purpose of protecting Medicaid beneficiaries and the state budget from excessive prescription drug costs. The bill is framed as a transparency and accountability measure, and there are no recorded votes or committee transcripts showing formal opposition or amendment debate. Based on the text alone, the measure appears to have been introduced as a policy response to concerns about PBM practices and Medicaid spending.
The main areas of contention are likely the bill’s restrictions on PBM and MCO operations, including the prohibition on spread pricing, the requirement for pass-through pricing, limits on prior authorization and step therapy, and the mandate that rebates and other manufacturer incentives benefit enrollees. Another likely point of dispute is the directive for EOHHS to study major structural changes to Medicaid pharmacy benefits, such as a single state PBM or carving pharmacy benefits out of managed care. These provisions would likely be supported by Medicaid advocates, patients, and independent pharmacies, but opposed or closely scrutinized by PBMs, managed care organizations, and possibly insurers concerned about cost, flexibility, and administrative burden.